Pfizer's PFE non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Victorian babies will be safer from Respiratory Syncytial Virus (RSV) this winter, with a long-acting immunisation available ...

The long-acting Respiratory Syncytial Virus (RSV) immunisation is now available free for eligible families until September 30 ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...